Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0PG8O
|
|||
| Former ID |
DIB010836
|
|||
| Drug Name |
Naltrexone
|
|||
| Synonyms |
Depotrex; Naltrel; Vivitrex; Vivitrol; Naltrexone Depot; IBS therapy, Pain Therapeutics; Irritable bowel syndrome therapy, Pain Therapeutics; PTI-901; XR-NTX; Naltrexone (sustained release), DAS; Naltrexone (sustained release), elbion; Naltrexone depot (injectable suspension), DrugAbuse Sciences; Naltrexone depot (injectable suspension), elbion; Opioid antagonists (irritable bowel syndrome), Pain Therapeutics; Naltrexone (low-dose), Pain Therapeutics; Naltrexone (polymer microcapsule depot, opioid addiction/alcohol dependency), Biotek; Naltrexone (transdermal, alcohol/opioid dependence), Syntropharma; Naltrexone (once-monthly controlled-release, Medisorb), Alkermes
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alcohol dependence [ICD-11: 6C40.2; ICD-10: F10.2] | Approved | [1] | |
| Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Phase 4 | [2], [3] | ||
| Company |
Tni biotech; DrugAbuse Sciences; Alkermes Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H23NO4
|
|||
| Canonical SMILES |
C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O
|
|||
| InChI |
1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1
|
|||
| InChIKey |
DQCKKXVULJGBQN-XFWGSAIBSA-N
|
|||
| CAS Number |
CAS 16590-41-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9462, 596067, 11466144, 11467264, 11485807, 11653758, 14753731, 14875729, 39383995, 46505333, 47206838, 47350797, 47647883, 47722000, 48095907, 48170809, 48244798, 49698353, 49993104, 53787920, 57362014, 80591843, 85787880, 92308967, 93166563, 93815010, 103915329, 104222111, 124886894, 124886895, 127334962, 127334963, 127334964, 127334965, 127334966, 127770775, 131283791, 134337689, 134993601, 135650687, 137001356, 141566780, 143492741, 144205560, 152134015, 152233304, 152258923, 160647768, 160964048, 166653673
|
|||
| ChEBI ID |
CHEBI:7465
|
|||
| ADReCS Drug ID | BADD_D01527 ; BADD_D01528 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor (OPR) | Target Info | Antagonist | [1], [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1639). | |||
| REF 3 | ClinicalTrials.gov (NCT02478489) Alcohol Use Disorder hOsPital Treatment Trial. | |||
| REF 4 | An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.